Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Poteligeo for the Treatment of Mycosis Fungoides and Sezary Syndrome

Drug Name

Poteligeo® (mogamulizumab-kpkc)

Developer

Kyowa Kirin

Therapy Class

Monoclonal antibody

Product Description

CC chemokine receptor type 4 (CCR4)- directed monoclonal antibody

Current Indication

Mycosis fungoides and Sézary syndrome

Market Sector

Oncology

Development Status

Approved in the US, Europe, and Japan
Expand
Close
Close
Close

Go Top